Healthcare & Life Sciences
CRISPR Therapeutics
CRISPR Therapeutics, co-developer with Vertex Pharmaceuticals of Casgevy -- the first FDA-approved CRISPR gene-editing therapy -- reported Q1 2026 Casgevy revenue of $43 million, with the companies projecting revenue to nearly triple over 2026 on expanding patient access, rising infusion volumes, and broader insurance coverage. The company held $2.44 billion in cash as of March 2026 (up from $1.98 billion at year-end, partly from a $585 million convertible note raise) and is advancing a diversified pipeline spanning in vivo liver editing, siRNA programs, an autoimmune/oncology CAR-T platform (zugo-cel), and regenerative medicine for diabetes, while pursuing first-half 2026 regulatory submissions to expand Casgevy's label to patients aged 5-11.
Leading Indicators
Hiring and patent filing trends — the underlying numbers Momentum is computed from. Insider filing activity is tracked separately under Sources below.
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
2 sources · 1 government/SEC filing · 74% avg. source confidence
- U.S. Securities and Exchange Commission (EDGAR) — CRISPR Therapeutics FY2025 Annual Report (Form 10-K), filed with the SEC95% source confidence
- CRISPR Therapeutics IR / PackGene Biotech — CRISPR Therapeutics reports Q1 2026 Casgevy revenue growth, pipeline expansion52% source confidence
Insider Filing Activity
Counts filing frequency only — transaction direction/size wasn't parseable from the sampled filings · sourced from SEC EDGAR · as of Jul 28, 2026
Dependency Map
What CRISPR Therapeutics depends on below, and who depends on CRISPR Therapeutics above — click any node to make it the new center, 3 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
CRISPR Therapeutics's Timeline
A sourced, dated history of CRISPR Therapeutics's key moments — founding to present.
2026-Q1 · Casgevy revenue reaches $43M, cash position strengthens to $2.44B
CRISPR Therapeutics reported Q1 2026 Casgevy revenue of $43 million, with Vertex and CRISPR projecting revenue to nearly triple in 2026; cash, equivalents and marketable securities reached $2.44 billion, up from $1.98 billion at year-end, aided by $585.4 million in net proceeds from convertible senior notes.